BACKGROUND: The recreational drug, Salvinorin A, derived from the plant of Salvia divinorum, is a potent and selective kappa-opioid receptor agonist. The abuse of selective k-agonists is a novel phenomenon, the mechanism of which is not fully understood. METHODS: We investigated salvinorin A given SC on the conditioned place preference (.05-160 microg/kg) and intracerebroventricular (ICV) self-administration (.01-1 microg/infusion) paradigms, in Wistar rats. RESULTS: The present results demonstrate the rewarding effects of Salvinorin A in a range of doses between .1 and 40 microg/kg SC for conditioned place preference test and .1-.5 microg/infusion for ICV self-administration. Highest doses (160 microg/kg for conditioned place preference test and 1 microg/infusion for ICV self-administration) were aversive. The rewarding effect was antagonized by intraperitoneal (IP) pretreatment with the cannabinoid CB(1) receptor antagonist, rimonabant [N-piperidino-5-(4-chlorophenyl)1-(2,4-dichloro phenyl)-4 methyl pyrazole 3-carboxamide] (1 mg/kg), and the kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI) (10 mg/kg). In the shell of nucleus accumbens, dopamine extracellular levels were increased after administration of salvinorin A (40 microg/kg SC), reaching a maximum value of about 150%. CONCLUSIONS: These data provide the demonstration of the rewarding effects of Salvinorin A through an interaction between kappa-opioid and (endo)cannabinoid system in rats.
BACKGROUND: The recreational drug, Salvinorin A, derived from the plant of Salvia divinorum, is a potent and selective kappa-opioid receptor agonist. The abuse of selective k-agonists is a novel phenomenon, the mechanism of which is not fully understood. METHODS: We investigated salvinorin A given SC on the conditioned place preference (.05-160 microg/kg) and intracerebroventricular (ICV) self-administration (.01-1 microg/infusion) paradigms, in Wistar rats. RESULTS: The present results demonstrate the rewarding effects of Salvinorin A in a range of doses between .1 and 40 microg/kg SC for conditioned place preference test and .1-.5 microg/infusion for ICV self-administration. Highest doses (160 microg/kg for conditioned place preference test and 1 microg/infusion for ICV self-administration) were aversive. The rewarding effect was antagonized by intraperitoneal (IP) pretreatment with the cannabinoid CB(1) receptor antagonist, rimonabant [N-piperidino-5-(4-chlorophenyl)1-(2,4-dichloro phenyl)-4 methyl pyrazole 3-carboxamide] (1 mg/kg), and the kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI) (10 mg/kg). In the shell of nucleus accumbens, dopamine extracellular levels were increased after administration of salvinorin A (40 microg/kg SC), reaching a maximum value of about 150%. CONCLUSIONS: These data provide the demonstration of the rewarding effects of Salvinorin A through an interaction between kappa-opioid and (endo)cannabinoid system in rats.
Authors: Gabriella Aviello; Francesca Borrelli; Francesca Guida; Barbara Romano; Kevin Lewellyn; Maria De Chiaro; Livio Luongo; Jordan K Zjawiony; Sabatino Maione; Angelo A Izzo; Raffaele Capasso Journal: J Mol Med (Berl) Date: 2011-04-16 Impact factor: 4.599
Authors: David N Potter; Diane Damez-Werno; William A Carlezon; Bruce M Cohen; Elena H Chartoff Journal: Biol Psychiatry Date: 2011-07-14 Impact factor: 13.382
Authors: Mohini Ranganathan; Ashley Schnakenberg; Patrick D Skosnik; Bruce M Cohen; Brian Pittman; R Andrew Sewell; Deepak Cyril D'Souza Journal: Biol Psychiatry Date: 2012-07-18 Impact factor: 13.382
Authors: D Matthew Walentiny; Robert E Vann; Jonathan A Warner; Lindsey S King; Herbert H Seltzman; Hernán A Navarro; Charles E Twine; Brian F Thomas; Anne F Gilliam; Brian P Gilmour; F Ivy Carroll; Jenny L Wiley Journal: Psychopharmacology (Berl) Date: 2010-03-31 Impact factor: 4.530
Authors: Bruce E Blough; Antonio Landavazo; Ann M Decker; John S Partilla; Michael H Baumann; Richard B Rothman Journal: Psychopharmacology (Berl) Date: 2014-05-07 Impact factor: 4.530